文献速递支持与姑息治疗

右雷佐生与儿童癌症幸存者的长期心脏功能

Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.
PubMed 文献 · J Clin Oncol · 2023-01-20

该研究纳入儿童肿瘤幸存者,评估右雷佐生对长期心脏功能的保护作用。在49家机构中评估195名参与者,随访至诊断后18.1±2.7年。右雷佐生与左心室缩短分数和射血分数的改善相关,且降低左心室功能低下风险(OR 0.24,95%CI 0.07-0.81)。

要点

  • 右雷佐生与左心室缩短分数绝对差异+1.4%及射血分数绝对差异+1.6%相关。
  • 右雷佐生与左心室功能低下风险降低相关(OR 0.24,95%CI 0.07-0.81)。
  • 保护性关联主要见于累积多柔比星剂量≥250 mg/m2者。

核心结论

  • 在儿童癌症年轻成年幸存者中,右雷佐生与初始蒽环类暴露近20年后的心脏保护效应相关。

研究设计与样本

  • 研究纳入儿童肿瘤学组和Dana Farber癌症研究所儿童急性淋巴细胞白血病联盟的四个随机试验(急性淋巴细胞白血病或霍奇金淋巴瘤,接受多柔比星±右雷佐生)和一个非随机试验(骨肉瘤,均接受多柔比星+右雷佐生),并纳入匹配的骨肉瘤幸存者(接受多柔比星未用右雷佐生)。
  • 五个试验中累积多柔比星剂量范围为100至600 mg/m2,右雷佐生以10:1 mg/m2比例在多柔比星前静脉推注。
  • 来自49家参与机构的195名参与者在癌症诊断后18.1±2.7年接受评估,51%暴露于右雷佐生,累积多柔比星剂量297±91 mg/m2。
  • 心脏功能通过二维超声心动图和血液生物标志物中心盲法分析前瞻性评估。
  • 多变量分析调整人口学特征、累积多柔比星剂量和胸部放疗。

主要发现

  • 右雷佐生与左心室缩短分数绝对差异+1.4%(95%CI 0.3至2.5)和射血分数绝对差异+1.6%(95%CI 0.0至3.2)相关。
  • 右雷佐生与B型利钠肽反映的心肌应力降低相关(-6.7 pg/mL,95%CI -10.6至-2.8)。
  • 右雷佐生与左心室功能低下(缩短分数<30%或射血分数<50%)风险降低相关(OR 0.24,95%CI 0.07至0.81)。
  • 保护性关联主要见于累积多柔比星剂量≥250 mg/m2者。

关键数值与推荐

  • 右雷佐生给药方案为10:1 mg/m2比例在多柔比星前静脉推注。
  • 累积多柔比星剂量范围100至600 mg/m2。
  • 左心室功能低下定义为缩短分数<30%或射血分数<50%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: For survivors of childhood cancer treated with doxorubicin, dexrazoxane is cardioprotective for at least 5 years. However, longer-term data are lacking. METHODS: Within the Children's Oncology Group and the Dana Farber Cancer Institute's Childhood Acute Lymphoblastic Leukemia Consortium, we evaluated four randomized trials of children with acute lymphoblastic leukemia or Hodgkin lymphoma, who received doxorubicin with or without dexrazoxane, and a nonrandomized trial of patients with osteosarcoma who all received doxorubicin with dexrazoxane. Cumulative doxorubicin doses ranged from 100 to 600 mg/m2 across these five trials, and dexrazoxane was administered uniformly (10:1 mg/m2 ratio) as an intravenous bolus before doxorubicin. Cardiac function was prospectively assessed in survivors from these trials, plus a matched group of survivors of osteosarcoma treated with doxorubicin without dexrazoxane. Two-dimensional echocardiograms and blood biomarkers were analyzed centrally in blinded fashion. Multivariate analyses adjusted for demographic characteristics, cumulative doxorubicin dose, and chest radiotherapy determined the differences and associations by dexrazoxane status. RESULTS: From 49 participating institutions, 195 participants were assessed at 18.1 ± 2.7 years since cancer diagnosis (51% dexrazoxane-exposed; cumulative doxorubicin dose 297 ± 91 mg/m2). Dexrazoxane administration was associated with superior left ventricular fractional shortening (absolute difference, +1.4% [95% CI, 0.3 to 2.5]) and ejection fraction (absolute difference, +1.6% [95% CI, 0.0 to 3.2]), and lower myocardial stress per B-type natriuretic peptide (-6.7 pg/mL [95% CI, -10.6 to -2.8]). Dexrazoxane was associated with a reduced risk of having lower left ventricular function (fractional shortening < 30% or ejection fraction < 50%; odds ratio, 0.24 [95% CI, 0.07 to 0.81]). This protective association was primarily seen in those treated with cumulative doxorubicin doses ≥ 250 mg/m2. CONCLUSION: Among young adult-aged survivors of childhood cancer, dexrazoxane was associated with a cardioprotective effect nearly 20 years after initial anthracycline exposure.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chow EJ, Aggarwal S, Doody DR, et al. Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer. J Clin Oncol. 2023. PMID: 36669148. doi:10.1200/JCO.22.02423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。